S. Myers

发表

Letter: infliximab induction regimens in steroid‐refractory acute severe colitis—a propensity score analysis. Authors' reply

S. Sebastian, S. Myers, 2020, Alimentary pharmacology & therapeutics.

Infliximab induction regimens in steroid‐refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis

N. Kennedy, J. Brooks, G. Moran, 2019, Alimentary pharmacology & therapeutics.

Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis

S. Sebastian, S. Subramanian, S. Myers, 2018, Digestive Diseases and Sciences.

Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study

Philip Smith, C. Lees, N. Bhala, 2021, The Lancet Gastroenterology & Hepatology.

React, reset and restore: Adaptation of a large inflammatory bowel disease service during COVID-19 pandemic.

S. Sebastian, J. Lisle, S. Myers, 2020, Clinical medicine.

Disease course of inflammatory bowel disease unclassified in a European population‐based inception cohort: An Epi‐IBD study

V. Andersen, L. Kupčinskas, S. Sebastian, 2019, Journal of gastroenterology and hepatology.

Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort—An ECCO-EpiCom Study

C. O'Morain, V. Andersen, L. Kupčinskas, 2017, Journal of Crohn's & colitis.

Budesonide treatment for microscopic colitis: systematic review and meta-analysis

M. Veysey, S. Sebastian, L. Jessica, 2019, European journal of gastroenterology & hepatology.

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Sarah F. Griffee, Susan M. Kilroy, Philip Smith, 2022, The Lancet Gastroenterology & Hepatology.

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Susan M. Kilroy, C. Lees, T. Ahmad, 2022, Nature Communications.

Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study

V. Andersen, L. Kupčinskas, S. Sebastian, 2018, Gut.

Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy

C. Lees, D. Franchimont, K. Farkas, 2020, Alimentary pharmacology & therapeutics.

Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study

V. Andersen, L. Kupčinskas, S. Sebastian, 2018, Journal of Crohn's & colitis.

DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study

C. Lees, D. Franchimont, S. Vavricka, 2020 .